Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Spain / NCT07047248
Starting soon Not applicable

Short- and Long-Term Effects of Whole-Body Photobiomodulation in Type II Diabetes Patients: A Protocol for a Controlled Clinical Trial

NCT07047248 · tracked via the Priya Life Science Spain tracker
Sponsor
University of Malaga
Phase
Not applicable
Started
2025-08-30
Last updated
2025-07-02

Condition(s) studied

Type II Diabetes Mellitus

Investigational drug(s) / intervention(s)

PBMPlacebo PBM

PBM: A whole body red light therapy (NovoTHOR®) will be carried out during 20 minutes

Placebo PBM: A placebo whole body red light will be carried out during 20 minutes

Study summary

The development of an integral and global treatment to improve the quality of life in those withType II Diabetes Patients is challenging, thus a whole body Photobiomodulation (PBM) therapy program is proposed as an effective option.

Eligibility

Sex
ALL
Min age
30 Years
Max age
70 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Adults aged 30 to 70 years. * Diagnosed with Type 2 Diabetes Mellitus (T2DM) according to the American Diabetes Association (ADA) criteria. * HbA1c levels between 6.5% and 10% at screening. * Stable diabetes management regimen (medications and lifestyle) for at least three months prior to enrollment Exclusion Criteria: * Presence of severe diabetic complications (e.g., end-stage renal disease, proliferative diabetic retinopathy). * History of photosensitivity or medical conditions exacerbated by light exposure. * Use of medications or supplements known to significantly alter glucose metabolism, other than current stable diabetes management. * Pregnant or lactating women.

Primary outcome measure(s)

  • Glucose Metabolism: Evaluated through changes in fasting blood glucose levels and HbA1c. — Follow-ups at 3 months and 6 months post-intervention
    • Glucose Metabolism: Evaluated through changes in fasting blood glucose levels and HbA1c.

Trial sites (1)

FacilityCityRegionStatus
Dr Granada Spain

More University of Malaga trials in Spain

Morphological and Mechanical Assessment in the Achilles Tendon After Radiofrequency Stimulation in Runners Starting soon
Efficacy of Hyaluronic Acid Cream in Preventing Foot Ulceration Risk in Patients With Type 2 Diabetes and Moderate-to-Severe Peripheral Neuropathy: A Randomized Clinical Trial. Enrolling by invitation
Slow Breathing and Resistance Exercise in Fibromyalgia Enrolling by invitation
Effectiveness of 5-week Digital Respiratory Practice in Children With Duchenne and Becker Muscular Dystrophies. Enrolling by invitation
Foot and Ankle Strengthening Program to Improve Physical Function in Menopausal Women (FAMEX) Starting soon

Other trials for the same condition

Oleanolic Acid as Therapeutic Adjuvant for Type 2 Diabetes Mellitus (OLTRAD STUDY) Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07047248 on ClinicalTrials.gov ↗ ← All trials in Spain